This is a working overview of GHRH analog, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-17. Anything still debated is marked as such rather than presented as settled.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
=== Types === Loose connective tissue - This type is mainly located under the epithelial membranes and glandular epithelium, attaching the epithelia to other tissues. It supports the blood vessels and nerves supplied to the epithelia. Additionally, it serves as the main site of inflammatory response within the body. Dense irregular connective tissue - the function of this type is binding at a high tensile strength between tissues to convert tension from one point.
Glucokinase (EC 2.7.1.2) is an enzyme that facilitates phosphorylation of glucose to glucose-6-phosphate. In medicine, the term is often used to refer to a specific hexokinase found in vertebrates and coded by the gene GCK in humans, but the EC number 2.7.1.2 (glucokinase) refers instead to an even more glucose-specific enzyme found in invertebrates and microorganisms. Unless otherwise specified, this article will be discussing the vertebrate enzyme. Glucokinase is expressed in cells of the liver and pancreas of humans and most other vertebrates. In each of these organs it plays an important role in the regulation of carbohydrate metabolism by acting as a glucose sensor, triggering shifts in metabolism or cell function in response to rising or falling levels of glucose, such as occur after a meal or when fasting. Mutations of the gene for this enzyme can cause unusual forms of diabetes or hypoglycemia. Glucokinase (GK) is a hexokinase isozyme, related homologously to at least three other hexokinases. All of the hexokinases can mediate phosphorylation of glucose to glucose-6-phosphate (G6P), which is the first step of both glycogen synthesis and glycolysis. However, glucokinase is coded by a separate gene and its distinctive kinetic properties allow it to serve a different set of functions. Glucokinase has a lower affinity for glucose than the other hexokinases do, and its activity is localized to a few cell types, leaving the other three hexokinases as more important preparers of glucose for glycolysis and glycogen synthesis for most tissues and organs.
In the 1918 general election, Lloyd George, hailed as "the Man Who Won the War", led his coalition into a khaki election. Lloyd George and the Conservative leader Bonar Law wrote a joint letter of support to candidates to indicate they were considered the official Coalition candidates—this "coupon", as it became known, was issued against many sitting Liberal MPs, often to devastating effect, though not against Asquith himself. The coalition won a massive victory: Labour increased their position slightly, but the Asquithian Liberals were decimated. Those remaining Liberal MPs who were opposed to the Coalition Government went into opposition under the parliamentary leadership of Sir Donald MacLean who also became Leader of the Opposition. Asquith, who had appointed MacLean, remained as overall Leader of the Liberal Party even though he lost his seat in 1918. Asquith returned to Parliament in 1920 and resumed leadership. Between 1919 and 1923, the anti-Lloyd George Liberals were called Asquithian Liberals, Wee Free Liberals or Independent Liberals. Lloyd George was increasingly under the influence of the rejuvenated Conservative party who numerically dominated the coalition. In 1922, the Conservative backbenchers rebelled against the continuation of the coalition, citing, in particular, Lloyd George's plan for war with Turkey in the Chanak Crisis, and his corrupt sale of honours. He resigned as prime minister and was succeeded by Bonar Law.
Substances found, according to the reports, are 1-Naphthol, naphthalene, Sevin, tarry residues, organochlorines, mercury, chromium, copper, nickel, lead, hexachlorethane, hexachlorobutadiene, pesticide HCH, volatile organic compounds and halo-organics. Many of these contaminants were also found in breast milk of women living near the area. Soil tests were conducted by Greenpeace in 1999. One sample (IT9012) from "sediment collected from drain under former Sevin plant" showed mercury levels to be at "20,000 and 6 million times" higher than expected levels. Organochlorine compounds at elevated levels were also present in groundwater collected from (sample IT9040) a 4.4 metres (14 ft) depth "bore-hole within the former UCIL site". This sample was obtained from a source posted with a warning sign which read "Water unfit for consumption". Chemicals that have been linked to various forms of cancer were also discovered, as well as trichloroethylene, known to impair foetal development, at 50 times above safety limits specified by the U.S. Environmental Protection Agency (EPA). In 2002, an inquiry by Fact-Finding Mission on Bhopal found a number of toxins, including mercury, lead, 1,3,5 trichlorobenzene, dichloromethane and chloroform, in nursing women's breast milk. A 2004 BBC Radio 5 broadcast reported the site is contaminated with toxic chemicals including hexachlorocyclohexane and mercury, held in open containers or loose on the ground.
== Applications == The highest selling transdermal patch in the United States is the nicotine patch, which releases nicotine in controlled doses to help with cessation of tobacco smoking. The first commercially available vapour patch to reduce smoking was approved in Europe in 2007. Two opioid medications used to provide round-the-clock relief for severe pain are often prescribed in patch form, fentanyl CII (marketed as Duragesic) and buprenorphine CIII (marketed as BuTrans). Hormonal patches: Estrogen patches are sometimes prescribed to treat menopausal symptoms (as well as post-menopausal osteoporosis) and to transgender women as a type of hormone replacement therapy. Contraceptive patches (marketed as Ortho Evra or Evra) and Testosterone CIII patches for both men (Androderm) and women (Intrinsa). Nitroglycerin patches are sometimes prescribed for the treatment of angina in lieu of sublingual pills. Transdermal scopolamine is commonly used as a treatment for motion sickness. The anti-hypertensive drug clonidine is available in transdermal patch form. Emsam, a transdermal form of the MAOI selegiline, became the first transdermal delivery agent for an antidepressant approved for use in the U.S. in March 2006. Daytrana, the first methylphenidate transdermal delivery system for the treatment of attention deficit hyperactivity disorder (ADHD), was approved by the FDA in April 2006. Secuado, a transdermal form of the atypical antipsychotic asenapine, was approved by the FDA in October 2019.
Sources: en.wikipedia.org
=== USSR 1933–1938 === Dorothea Eltenton wrote a book describing the family's life in the USSR. This was a happy time, despite primitive conditions compared with England, and she writes admiringly of the socialist society they experienced as it developed, with its community spirit, sexual equality and people's local democratic participation in decisions relating to work and public services. In particular they appreciated the free education and free health service. Her experience of maternity and post-natal care was favourably compared with that in the UK (a decade before the introduction of the National Health Service). On vacations George Eltenton was able to enjoy his passions for motorcycling and rock climbing.
=== Manufacturing === Packaging lines can have a variety of equipment types: integration of automated systems can be a challenge. All aspects of food production, including packaging, are tightly controlled and have regulatory requirements. Uniformity, cleanliness and other requirements are needed to maintain Good Manufacturing Practices. Product safety management is vital. A complete Quality Management System must be in place. Hazard Analysis and Critical Control Points is one methodology which has been proven useful. Verification and validation involves collecting documentary evidence of all aspects of compliance. Quality assurance extends beyond the packaging operations, through distribution and cold chain management.
Long-term exposure to outdoor and indoor air pollution adds a major environmental risk to public health in India. Particulate matter emissions from vehicles and factories are linked to a rise in chronic respiratory diseases, strokes, and cardiovascular disease, together adding an estimated 1.7 million premature deaths annually. India's early COVID-19 lockdown bought time to rapidly increase local testing and protective gear production; however, later waves of the virus overwhelmed the healthcare system, leading to severe shortages of oxygen and intensive care beds. Post-pandemic epidemiological studies estimate that cumulative excess deaths in India reached between 3.2 and 4.7 million.
== Donor selection == When grafts are taken from other animals, they are known as heterografts or xenografts. By definition, they are temporary biologic dressings which the body will reject within days to a few weeks. They are useful in reducing the bacterial concentration of an open wound, as well as reducing fluid loss. For more extensive tissue loss, a full-thickness skin graft, which includes the entire thickness of the skin, may be necessary. This is often performed for defects of the face and hand where contraction of the graft should be minimized. The general rule is that the thicker the graft, the less the contraction and deformity. Cell cultured epithelial autograft (CEA) procedures take skin cells from the person needing the graft to grow new skin cells in sheets in a laboratory; because the cells are taken from the person, that person's immune system will not reject them. However, because these sheets are very thin (only a few cell layers thick) they do not stand up to trauma, and the "take" is often less than 100%. Newer grafting procedures combine CEA with a dermal matrix for more support.Research is investigating the possibilities of combining CEA and a dermal matrix in one product. Experimental procedures are being tested for burn victims using stem cells in solution which are applied to the burned area using a skin cell gun. Recent advances have been successful in applying the cells without damage.
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.